07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Agilent sales and marketing update

Agilent's Dako A/S subsidiary launched Anti-CK 8/18 and Anti-TdT for cancer diagnosis. Anti-CK 8/18 is a rabbit mAb against cytokeratin 8 ( CK8 ; KRT8 ) and CK18 that is used to stain tissue samples...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

OxiGene, Boston Medical Center deal

The center, affiliated with Boston University Medical Center, will collaborate with the company under a sponsored research agreement to study OXGN's Neu-Sensamide and Oxi-104 as chemosensitizers of cordycepin (3'-deoxyadenosin). OXGN has an option to acquire...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Clinical News

Cordycepin: Phase I/II started

OncoVista began an open-label, U.S. Phase I/II trial to evaluate cordycepin plus pentostatin on days 1, 2 and 3 of a 21-day cycle in about 44 patients. The company acquired cordycepin, which has Orphan Drug...
08:00 , Feb 27, 2006 |  BioCentury  |  Strategy

The sum greater than the whole

It isn't uncommon for a company to have enough cash to develop a lead product but not enough to shepherd the rest of its pipeline. The danger is that the cash-strapped entity ends up being...
08:00 , Jan 13, 1997 |  BC Week In Review  |  Clinical News

Cordycepin, 3'-deoxyadenosine, and pentostatin, 2-deoxycoformycin: Update

Oxigene Inc. (OXGN), New York, N.Y.   Product: Cordycepin, 3'-deoxyadenosine, and pentostatin, 2-deoxycoformycin   Indication: Refractory TdT-positive, acute lymphoid leukemia   Status: A Phase I trial of the agents is expected to start in the...